Pridopidine (Huntexil) for Huntington's disease
NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
NIHR HSRIC. Pridopidine (Huntexil) for Huntington's disease. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015

Authors' objectives
Huntington's disease is a genetic condition that usually occurs in adults. It affects the central nervous system by damaging nerve cells in the brain. This causes problems with eyesight, movement, speaking and swallowing, and can also affect memory, moods and emotions. There is no cure for Huntington's disease, but there are treatments that can help control the symptoms. Pridopidine is a new drug which is given as a tablet to treat problems with movement in people who have Huntington's disease. Studies are currently underway to see how well it works and whether it is safe for patients to take. If pridopidine is licensed for use in the UK, it could offer a new treatment option for patients with Huntington's disease that may help with movement problems.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/pridopidine-huntexil-for-huntingtons-disease/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Huntington Disease; Piperidines

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000416

Date abstract record published
04/03/2016